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GLAUCOMA FOR THE FAMILY PHYSICIAN
GOAL 
To appreciate glaucoma as a sight-threatening 
condition. 
Recognize the risk factors of glaucoma. 
to provide a background to glaucoma, and describe 
the assessment and management of glaucoma patients. 
 finally to equip the Family Physician to be able to 









 A group of diseases characterized by progressive optic 
neuropathy with corresponding visual field defects where IOP is 
a major risk factor
Glaucoma causes irreversible damage to the optic nerve and no 
known treatment will restore lost vision. 
 According to The World Health Organization, although 70 
million people worldwide suffer from glaucoma, it is treatable if 
detected early, which means that those suffering from the disease 
can preserve their vision.
• WHO: The second 
biggest cause of 
blindness and visual 
impairment globally
• No.1 cause of 
irreversible blindness 
in most African 
populations
• A conservative estimation of the 
prevalence of glaucoma in Africa is 4% 
of people in the age group > 40 years
• >50% unaware of disease in developed 
world 
• >90% unaware in developing countries 
Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 
2006;90:262−267
The Global Burden of Glaucoma
Glaucoma Burden in Africa
-Blindness-
• Estimated to account for 4.4% of blindness 
in Africa
Naidoo K, Gichuhi S, Basáñez MG, et al. Prevalence and causes of vision loss in sub-Saharan Africa: 1990-2010. Br J Ophthalmol. 
2014;98:612−61 
• Nigeria-16.7% of total blindness burden
The Nigerian Blindness and visual impairment survey
• In Ghana, it accounts for 19.4% of all causes 
of blindness
Ghana Blindness and visual impairment survey
Glaucoma-classification
• Anatomic-Open angle or closed angle
• Presentation-Chronic or acute
• Cause-Primary or secondary
Classification of glaucoma
1. Primary open angle glaucoma (POAG)
2. Primary angle closure glaucoma (PACG)
3. Secondary glaucoma
4. Congenital glaucoma (CG)
• The most common type of glaucoma is primary 
open angle glaucoma also called chronic open 
angle glaucoma or chronic simple glaucoma and
Aqueous humour (aqueous)
• Aqueous is produced in the ciliary body
• It circulates around, and provides 
nourishment for, the lens
• It passes through pupil into the anterior 
chamber
• It leaves eye via the trabecular meshwork in 
the angle and enters the episcleral veins
GLAUCOMA
Intraocular pressure (IOP)
• IOP is a balance between aqueous production by 
the ciliary body and aqueous drainage through the 
angle
• If aqueous drainage is impaired, the IOP rises
• Normal IOP is below 21 mm Hg (defined as 2 
standard deviations above the mean)

Loss of neurones in optic nerve with age and disease











PRIMARY OPEN ANGLE GLAUCOMA (POAG)
• POAG is a chronic progressive optic 
neuropathy with gradual loss of nerve 
fibres
• 80% of patients have IOP > 21mmHg
• Enlargement of optic disc cup (loss of 
neurones)
• Progressive loss of visual field (tunnel 
vision)
POAG Symptoms
• Many asymptomatic “thief of sight”
• Bilateral but often asymmetric at time of Dx
• Early peripheral vision loss
• Late central vision loss
• Decreased contrast sensitivity
• Diminished color vision
Risk factors
• Race: African & Latino 
– Africans have higher mean IOP, 
larger c:d ratio, ↑ prevalence of 
POAG, earlier onset, 8x risk of 
blindness
• Age
– IOP increases with age
• FH
– 1st degree relatives at highest risk 
(10% risk of developing POAG)
– 25% of new POAG cases have + FH
• DM (mixed results)
• POAG/OHT is 2X - 3X more 
prevalent in DM
• DM or +GTT is more prevalent in 
POAG or steroid responders
• Myopia
– Same mean IOP as hyperopes but 3X 
POAG





• Most optic discs have a central 
physiological cup which usually 
has a diameter less than half of 
the disc diameter
• The cup is the part of the disc 
without nerve fibres and blood 
vessels
• Small optic discs have small cups 
and still be healthy
• Large optic discs can have large 




• Diagnosis of glaucoma depends on the 
presence of the following three components: 
• Raised IOP (normal IOP is 10–21 mmHg). 
• Structural damage to the optic nerve head 
(optic disc). 
• Loss of visual field in a characteristic way.
Assessment of patients with glaucoma
• Assessment includes the measurement of the IOP, clinical 
evaluation of the optic disc, and a visual field evaluation.
• Different instruments can be used to measure the IOP. 
• The Goldmann applanation tonometer is the standard 
tonometer used by ophthalmologists and some optometrists.
• Most optometrists use an air-puff tonometer, Icare tonometer 
and tonopens
• An examination with a direct ophthalmoscope gives an 
excellent view of the optic disc. 
• The use of fundoscopy and pupil reactions as screening tests 
for all persons at risk (age group > 40 years) have proved to be 
suitable screening tools for glaucoma.





• Visual field defects are difficult to detect clinically without 
specialised equipment until late in the disease (loss of > 50% of 
the nerve fibres). 
• Arcuate scotomas begin in superior or inferior visual field
• These join up to produce a ring scotoma
• This extends to produce tunnel vision
• Eventually central vision is lost




Aims of treatment of POAG
• To stabilise visual field loss
• To reduce risk of further progression
• To maintain central visual field
• Once lost, visual field cannot be 
recovered
Management of glaucoma
• POAG can be managed by:
–Observation: mainly ocular hypertension
–Medical therapy: drops (rarely oral therapy)





– Beta-blockers e.g. Timolol
– Parasympathomimetic eg pilocarpine
– Prostaglandin analogues e.g. xalatan
– Carbonic anhydrase inhibitors e.g dorzolamide
• Oral
– Carbonic anhydrase inhibitors e.g. diamox
Side effects if medical therapy
 Beta blockers can cause postural hypotension, bronchospasm and worsening of 
asthma, impotence, heart block and congestive cardiac failure.
 Topical allergy to the drug, or the preservative in the drops, can cause itching, 
swelling of eyelids and eczema of the periocular skin.
 Side effects of acetazolamide (Diamox) can include nausea, paraesthesia, electrolyte 
disturbances and renal stones.
 Prostaglandins can cause an increase in melanin pigmentation in the iris, blurred 
vision, redness of the eyelids and anterior uveitis, upper respiratory tract infection 
symptoms, chest pain and miscarriages.
Angle closure glaucoma
• Primary angle closure glaucoma (ACG) is caused by 
appositional or synechial closure of the anterior chamber 
angle, due to a number of mechanisms.
• This is a sight threatening emergency, involving painful loss of 
vision, due to sudden and total closure of angle. 
• It is probably the best known type of glaucoma.
ANGLE CLOSURE GLAUCOMA
• In ACG, apposition of the lens to the back of the iris prevents 
the flow of aqueous humour from the posterior chamber to 
the anterior chamber.
• This is more likely to occur when the pupil is semi-dilated at 
night.
• Aqueous humour that collects behind the iris pushes the iris 
onto the trabecular meshwork, preventing the drainage of the 
aqueous humour from the eye, and resulting in a rapid 
increase in IOP.
Acute angle  closure glaucoma: mechanism
• Aqueous is produced in the ciliary body
• It circulates around the lens and through the pupil into the anterior chamber
• It leaves the eye at the angle
• In some eyes, when the pupil is mid-dilated, aqueous cannot pass through the 
pupil
• The iris is pushed against the cornea and the angle closes
• This leads to a rapid build up of pressure, hence the severe pain
Acute angle closure  glaucoma: signs





• Symptoms of an acute attack are a painful red eye, 
headache and, frequently, nausea and vomiting. 
• Vision is blurred, because the cornea becomes 
oedematous. 
• There may be a history of similar attacks in the past that 
were aborted by going to sleep, because the pupil 
constricts and may pull the peripheral iris out of the 
angle, ending the attack. 
Signs
• Impaired visual acuity
• Red and painful eye
• Cornea is hazy, because of the oedema
• Pupil is semi-dilated and fixed, with no reaction to light
• On palpation, the affected eye feels harder than the other eye
• If the patient is seen shortly after an attack has resolved, none 
of these signs may be present. Therefore it is important to take 
a good history.
Groups at risk of developing acute ACG
• Hypermetropic (far-sighted) patients
• Women (3–4 times higher)
• Eskimos (40 times higher) and Asians have a 
higher incidence than Caucasians
• Black patients have a low risk for developing ACG
• Highest incidence: 55–65 years of age
Medical treatment for the acute attack
• Acetazolamide (Diamox®) 500 mg IV or per os
• Hyperosmotic agents, e.g. glycerine or mannitol
• Topical miotics, e.g. pilocarpine 2%, to constrict the pupil and 
pull the iris from the trabecular meshwork
• Analgesics
• Antiemetics
• Lie supine for one hour so that the effect of gravity can pull the 
iris from the angle.
Surgery
• Surgery is the treatment of choice for ACG and is performed as 
soon as the cornea has cleared after the acute attack.
• A peripheral iridectomy or laser iridotomy can be performed.
• Both eyes are treated, because the risk of angle closure in the 
other eye is significant.
• Prophylactic treatment: Pilocarpine drops can prevent an acute 
attack until the patient can be referred for surgery or laser 
treatment.
Secondary glaucoma
• In secondary glaucoma elevated IOP results in 
progressive optic disc neuropathy and visual field 
defects. 
• The condition is caused by other ophthalmological or 
extraocular diseases and certain drugs. 
• The FP must be aware of the underlying pathology that 
may cause secondary glaucoma, in order to prevent or 
delay the progression of glaucoma.
common causes of secondary open angle
glaucoma
• Treatment with steroids (topical and systemic, asthma inhalers, 
nasal sprays, and even topical ointments)
• Particles that block the trabecular meshwork (malignant cells, red 
blood cells, inflammatory cells or pigment)
• Membranes in the anterior chamber angle
• Trauma to the trabecular meshwork
• Neovascularisation in the angle, e.g. in diabetics, or after central 
retinal vein occlusion
• Pseudoexfoliation syndrome
MANAGEMENT OF SECONDARY GLAUCOMA
• ADDRESS UNDERLYING CASE
• MEDICAL OR SURGICAL MEASURES TO REDUCE IOP
Congenital glaucoma
• In congenital glaucoma (CG), a developmental malformation of 
the anterior chamber angle causes glaucoma. 
• CG calls for early assessment and surgical intervention to 
prevent structural damage to the optic disc and allow visual 
development.
• CG is frequently bilateral and associated with other defects. It 
needs early diagnosis to avoid irreversible blindness.
CONGENITAL GLAUCOMA







• increased corneal diameter 
(> 12 mm), increased size of 
the eye or buphthalmos (due 
to raised IOP and elastic 
sclera)
• pale optic disc.

Treatment
• Treatment involves surgery (goniotomy or trabeculotomy)

Conclusion
• Identify patients with signs and symptoms suggestive of acute, 
angle closure glaucoma and institute management, in addition to 
referral to the ophthalmologist.
• Engage in screening of patients with symptoms and signs 
suggestive of open angle glaucoma.
• Explain and reassure the patient, because this is a chronic 
condition.
• discuss the impact of the visual loss with patients and their families  
i.e driving cessation and limitation, bumping into objects and falls.
Conclusion
• Refer for reassessment if the patient has symptoms of 
progression or side effects from the treatment.
• Educate patients about screening of family members and the 
genetic factors in glaucoma. (First degree relatives have a 10% 
chance of developing glaucoma.)
• Refer a patient who has had previous glaucoma surgery (even 
years before), and who presents with a red eye or signs of 
infection, back to the ophthalmologist immediately, to exclude 
blebitis or endophthalmitis
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